Key result
Three mRNA-1273 doses produce detectable Omicron neutralizing responses in only ~18% of transplant patients.
Why the study?
Three doses of mRNA COVID-19 vaccine are recommended for transplant recipients, but their immunogenicity specifically relating to the Omicron variant is not well studied.
Does three doses of mRNA-1273 vaccine produce neutralizing antibody responses against the Omicron variant in transplant patients?
Cohort (n=60)
Does three doses of mRNA-1273 vaccine produce neutralizing antibody responses against the Omicron variant in transplant patients?
Three doses of mRNA-1273 vaccine result in poor neutralizing antibody responses against the SARS-CoV-2 Omicron variant in solid organ transplant recipients.
Answers are grounded in this paper and cite their sources.
May indicate limited Omicron protection in transplant recipients; leaves open need for tailored boosting strategies in immunocompromised patients.
The SARS-CoV-2 virus Omicron variant has now supplanted wild-type virus as the dominant circulating strain globally. Three doses of mRNA COVID-19 vaccine are recommended for transplant recipients as their primary vaccine series. However, the immunogenicity of mRNA vaccines as they specifically relate to the Omicron variant are not well studied. We analyzed Omicron-specific neutralization in transplant recipients after three-doses of mRNA-1273 vaccine. Neutralization was determined using a SARS-CoV-2 spike pseudotyped lentivirus assay with constructs for Omicron and Delta variants. A total of 60 transplant patients (kidney, kidney-pancreas, lung, heart, liver) were analyzed 1 month and 3 months after completion of three doses of mRNA-1273. At 1 month, 11/60 (18.3%) patients had detectable neutralizing antibody responses to Omicron (log 10 ID50 of 2.38 [range 1.34–3.57]). At 3 months, 8/51 (15.7%) were positive (median log 10 ID50 [1.68; range 1.12–3.61; approximate fivefold reduction over time]). The proportion of positive patients was lower for Omicron versus wild-type, and Omicron vs. Delta ( p < .001). No demographic variables were found to be significantly associated with Omicron response. Many patients with a positive anti-RBD response still had undetectable Omicron-specific neutralizing antibody. In conclusion, three doses of mRNA vaccine results in poor neutralizing responses against the Omicron variant in transplant patients.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2022) conducted a cohort in Transplant recipients (n=60). mRNA-1273 vaccine was evaluated on Detectable neutralizing antibody responses to Omicron at 1 month. Three doses of the mRNA-1273 vaccine resulted in poor neutralizing responses against the Omicron variant in transplant patients, with only 18.3% having detectable responses at 1 month.
Synapse has enriched 10 related papers. Consider them for comparative context: